Breast Conserving Surgery: Has the Standard of Care Enhanced Outcomes for Patients?

• 作者: Rodrigo Arrangoiz Jeronimo Garcialopez De Llano Maria Fernanda Mijares Gonzalo Fernandez-Christlieb Vanitha Vasudevan Amit Sastry Adrian Legaspi
• 来源期刊: 乳腺癌(英文)
• 学科: 医学
• 关键词: Breast Conserving Surgery (BCS) Disease-Free Survival (DFS) Recur-rence-Free Survival (RFS) Distant-Disease-Free Survival (DDFS) Overall Sur-vival (OS) Ductal Carcinoma in Situ (DCIS) Neoadjuvant Chemotherapy (NAC)
• 年，卷（期）: 2021,（1）
• 页码范围: 1-23
• 页数: 23页
• 分类号: R73

摘要

Breast Conserving Surgery (BCS) is a rapidly emerging field increasingly adopted to facilitate breast conservation and preserve breast aesthetics. Since the publicatio</span><span style="font-family:Verdana;">n of the Randomized Controlled Trials (RCTs) of Breast Conserving Surgery versus mastectomy in early breast cancer, the adoption of BCS for breast cancer patients’ surgical management has been comprehensive. A computerized bibliographic search was performed on PubMed/MEDLINE,</span><span style="font-family:Verdana;"> Embase, Google Scholar and Cochrane library databases. This article aims to perform a thorough review of new data regarding invasive cancer and margins while evaluating patient outcomes related to BCS after neoadjuvant chemotherapy focusing on margins, imaging evaluation, the extent of resection, and local regional recurrence outcomes. The growth pattern and biopsy of Ductal Carcinoma </span><i><span style="font-family:Verdana;">In Situ</span></i><span style="font-family:Verdana;"> (DCIS) differ from invasive cancer, impacting margins. It is essential to understand how the Society of Surgical Oncology (SSO) DCIS margin guideline has influenced practice. Early breast cancer surgical management should be unique to each patient, driven by evidence-based medicine, and focused on specific clinical, histological, and molecular characteristics of the tumor. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">The current management for early breast cancer should be tailored and evidence-based to each patient based on the clinical, histological and molecular characteristics of the tumor. Presumably, the standard of care in BCS has enhanced the outcomes for this patient population. This review made by peers will help surgeons to stay up to date with the current literature and help them manage breast cancer while improving multiple clinical parameters such as Disease-Free Survival (DFS), Recurrence-Free Survival (RFS) and most importantly Overall Surviva